Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 5:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 83 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo - Exenatide - Exenatide Clear all
Completed Phase 4 Interventional Results available

Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia

NCT02417142
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Exenatide, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients

NCT00500370
View directory record Official record
Conditions
Obesity
Interventions
exenatide, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Peoria, Arizona • Tucson, Arizona • Santa Ana, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes

NCT01928329
View directory record Official record
Conditions
Type I Diabetes
Interventions
Exenatide (Bydureon®), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women

NCT00456885
View directory record Official record
Conditions
Obesity, Impaired Glucose Tolerance
Interventions
exenatide, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
25 Years to 60 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 25, 2026, 5:22 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

NCT01381926
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Bone Remodeling
Interventions
exenatide, Saline
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
45 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 25, 2026, 5:22 AM EDT
Terminated Phase 3 Interventional Results available

A Trial to Determine the Efficacy and Safety of Presendin in IIH

NCT05347147
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension
Interventions
Presendin, Placebo
Drug
Lead sponsor
Invex Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Aurora, Colorado • Miami, Florida • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 25, 2026, 5:22 AM EDT
Withdrawn Phase 1 Interventional

Exenatide For Reducing the Reinforcing Effects of Cocaine

NCT06252623
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Exenatide, Placebo
Drug
Lead sponsor
Christopher D. Verrico
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 25, 2026, 5:22 AM EDT
Terminated Phase 4 Interventional Results available

GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes

NCT03029351
View directory record Official record
Conditions
Type2 Diabetes, Kidney Diseases
Interventions
Exenatide Extended Release for Inj Susp 2 MG, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

NCT00765817
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
placebo, exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
40
States / cities
Peoria, Arizona • Phoenix, Arizona • Buena Park, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2016 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity

NCT02664441
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Exenatide, placebo
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
10 Years to 25 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Minneapolis, Minnesota • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Type 2 Diabetes Mellitus

NCT01064687
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265, Exenatide, Placebo, Metformin, Pioglitazone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
78
States / cities
Goodyear, Arizona • Phoenix, Arizona • Cathedral City, California + 75 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 4 Interventional Results available

Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM

NCT02981069
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin, Exenatide, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus

NCT01652729
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Exenatide once weekly suspension, Sitagliptin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes

NCT01455857
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ITCA 650, ITCA placebo
Drug · Other
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
121
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 102 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2015 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Antidiabetic Medications on the Postprandial State in Prediabetes

NCT02104739
View directory record Official record
Conditions
Prediabetes, Obesity
Interventions
Exenatide, Saxagliptin, Exenatide extended-release (ER), Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
30 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 25, 2026, 5:22 AM EDT
Terminated Phase 2 Interventional Results available

A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease

NCT01255163
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Exendin-4 SC, Placebo SC
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

NCT02119819
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2944876, Exenatide extended-release, Placebo, Metformin
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
31
States / cities
Concord, California • Fresno, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 2 Interventional

Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

NCT00044694
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Placebo 0.01 mL, Placebo 0.02 mL, Placebo 0.03 mL, Placebo 0.04 mL, AC2993 2.5 mcg, AC2993 5.0 mcg, AC2993 7.5 mcg, AC2993 10.0 mcg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
33
States / cities
Birmingham, Alabama • Anaheim, California • Bellflower, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2015 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity

NCT02496611
View directory record Official record
Conditions
Severe Obesity
Interventions
Weight loss with pharmacotherapy, Weight loss without pharmacotherapy
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 2, 2022 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

NCT02229396
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Exantide with Dapagliflozin, Exentide, Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
76
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2018 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Exenatide as Monotherapy

NCT00381342
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Idaho Falls, Idaho • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 22, 2015 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension

NCT00894322
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide once weekly, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
19 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 17, 2015 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 2 Interventional

Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes

NCT00241423
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Washington D.C., District of Columbia • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2015 · Synced Sep 25, 2026, 5:22 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects

NCT02802514
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Albiglutide 50mg, Albiglutide matching placebo, Exenatide 10microgram, Exenatide placebo (saline)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Sep 25, 2026, 5:22 AM EDT